1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Drugs Made In America Acquisition Corp. Units

Drugs Made In America Acquisition Corp. Units

DMAAU
Drugs Made In America Acquisition Corp. UnitsUS flagNASDAQ Global Market
10.99
USD
- -
- -
368.65MMarket Cap
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
- -
Book Value per Share
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
6
7
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
- -
- -
- -
Working Capital
-1
- -
- -
LT Debt
- -
- -
- -
Total Equity
- -
233
235
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
- -
2.89

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
ST Debt
- -
- -
LT Borrowings
- -
- -
LT Finance Leases
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
34
34
Market Capitalization
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Total Current Assets
- -
- -
Cash, Cash Equivalents & STI
- -
- -
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
- -
- -
Payables & Accruals
- -
- -
ST Debt
- -
- -
Deferred Revenue
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-95,116.31%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Roger Bendelac
Full Time Employees
2
Sector
Financial Services
Industry
Shell Companies
Address
420 Lexington Avenue New York NY United States of America 33301
IPO Date
Jan 27, 2025
CIK
0002028614
Website
dmaacorp.com
Similar Companies
UTA Acquisition Corporation (UTAAU)
International Media Acquisition Corp. (IMAQR)
AP Acquisition Corp. (APCA)
TCV Acquisition Corp. (TCVA)
Nabors Energy Transition Corp. II Class A Ordinary Shares (NETD)
JATT Acquisition Corp (JATT-WT)
Business
Drugs Made In America Acquisition Corp. operates as a specialized acquisition entity. It was established with the objective of executing a significant business combination, such as a merger, asset acquisition, or similar transaction, with one or more target companies. The firm focuses on identifying U.S.-based businesses within the pharmaceutical or biotechnology sector, particularly those dedicated to the development, manufacturing, or commercialization of essential drug products for the American market, aiming to bolster domestic supply chain resilience. The company commenced operations on May 23, 2024, and maintains its principal offices in Fort Lauderdale, Florida.

Company News

APIChatGPT

  • defenseworld.net

    Drugs Made in America Acquisition (NASDAQ:DMAAU) Shares Down 0% – Time to Sell?

  • defenseworld.net

    Drugs Made in America Acquisition (NASDAQ:DMAAU) Trading 0.2% Higher – What’s Next?

  • defenseworld.net

    Drugs Made in America Acquisition (NASDAQ:DMAAU) Stock Price Down 0.6% – Here’s Why

  • globenewswire.com

    Drugs Made in America Acquisition Corp. Announces Advisory Team